---
schema_version: "secwatch.filing_event.v1"
accession: "0001837607-25-000084"
form_type: "8-K"
ticker: "AEON"
cik: "0001837607"
company_name: "AEON Biopharma, Inc."
filed_at: "2025-11-14T23:59:59+00:00"
generated_at: "2026-05-16T19:54:57.736248+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# AEON Biopharma reports positive ABP-450 biosimilarity data, secures $6M PIPE and debt reduction

## Summary
- ABP-450 shows 100% amino-acid sequence identity to BOTOX (93-99% coverage across five proteins) and highly similar functional characteristics.
- FDA Type 2a meeting scheduled for November 19, 2025 to review analytical package ahead of biosimilar pathway.
- $6M PIPE and Daewoong note exchange expected to reduce outstanding debt by over 90% and extend cash runway into Q2 2026.
- Cash and equivalents $5.9M as of Sep 30, 2025; combined financing expected to fund operations through Q2 2026.
- ABP-450 has global approval in 69 countries, supporting fully scaled manufacturing platform.

## SEC filing metadata
- accession: 0001837607-25-000084
- form_type: 8-K
- ticker: AEON
- cik: 0001837607
- company_name: AEON Biopharma, Inc.
- filed_at: 2025-11-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1837607/000183760725000084/0001837607-25-000084-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1837607/000183760725000084/aeon-20251114x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001837607-25-000084
- JSON: https://secwatch.observer/filing/0001837607-25-000084.json
- Plain text: https://secwatch.observer/filing/0001837607-25-000084.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.